한글목차

다발성 경화증 치료제 시장은 2030년까지 338억 달러에 달할 전망입니다.

2023년에 213억 달러로 추정된 다발성 경화증 치료제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 6.9%를 나타낼 전망이며, 2030년에는 338억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 면역억제제는 복합 연간 성장률(CAGR) 7.5%를 나타낼 전망이며 성장을 지속하여, 분석 기간 종료 시 132억 달러에 달할 것으로 예측됩니다. 면역억제제 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 5.3%를 나타낼 전망입니다.

미국 시장은 56억 달러로 추정되며, 중국은 복합 연간 성장률(CAGR) 6.6%를 나타낼 전망이며 성장 예측됩니다.

미국의 다발성 경화증 치료제 시장은 2023년 56억 달러로 추정됩니다. 세계의 2위 경제대국인 중국은 2030년까지 54억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 6.6%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 6.4%와 5.8%를 나타낼 전망이며 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 5.4%를 나타낼 전망입니다.

주요 동향과 촉진요인

다발성 경화증(MS)은 만성 진행성 신경퇴행성 질환이며, 면역계가 신경 섬유를 덮는 미엘린 칼집을 공격하고 뇌와 신체 사이의 정보 전달에 장애를 일으키는 것을 특징으로 합니다. MS의 치료는 발작의 빈도와 중증도를 줄이고, 질병의 진행을 늦추고, 증상을 관리하는 질병 수정 요법(DMT)의 도입으로 극적으로 개선되었습니다. 이러한 치료에는 인터페론과 글라티라머 아세테이트와 같은 주사제, 핑고리모드 및 디메틸 푸마레이트와 같은 경구 약물, 나탈리주맙과 오클레리주맙과 같은 점적 치료가 포함됩니다. 다양한 치료법이 있기 때문에 질병의 중증도, 환자가 경험하는 특정 증상, 환자의 라이프 스타일 기호에 맞게 개별화 된 치료 계획이 가능합니다.

최근 몇 년동안 MS 치료의 초점은 돌이킬 수없는 신경학적 손상을 예방하기 위해 조기 개입과보다 적극적인 치료 전략으로 이동하고 있습니다. MS의 질병 과정에 관여하는 특정 경로를 표적으로 하는 새로운 치료법이 개발되었으며, 기존의 치료법에 비해 효능과 안전성이 개선될 수 있습니다. 또한 MS 환자의 QOL을 개선하기 위한 생활습관, 재활, 증상관리요법의 역할에 대해서도 조사가 진행되고 있습니다. MS 치료에 대한 이러한 전인적인 접근법은 질병을 효과적으로 관리하는 데 필수적인 것으로 인식되고 있습니다.

다발성 경화증 치료제 시장의 성장은 신규 치료 표적 및 약물 개발로 이어지는 MS 병태의 이해에 대한 지속적인 발전 등 여러 요인들에 의해 견인되고 있습니다. 세계의 MS의 유병률이 상승하고 보다 효과적이고 안전한 치료법에 대한 수요가 높아지고 있는 것이 시장 확대에 박차를 가하고 있습니다. 또한 규제 당국의 혁신적인 신약 승인은 임상 현장 채용을 가속화하고 있습니다. 또한 인지, 교육, 신치료에 대한 접근을 촉진하는 견고한 환자 지원 네트워크도 시장을 지원하고 있으며, MS 치료의 최신 진보로 환자가 확실히 혜택을 받을 수 있게 되었습니다. 또한 진단 기술의 향상은 질병의 최적 관리에 필수적인 조기 발견과 치료 시작을 지원합니다.

조사 대상 기업 예(주목의 49사)

• AB Science SA
• Acorda Therapeutics, Inc.
• Banner Life Sciences
• Biogen, Inc.
• Biohaven, Ltd.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Janssen Sciences Ireland UC
• MediciNova, Inc.
• Novartis International AG
• Opexa Therapeutics, Inc.
• Sandoz Group AG
• Sanofi SA
• Teva Pharmaceuticals USA, Inc.
• TG Therapeutics, Inc.;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Multiple Sclerosis Drugs Market to Reach US$33.8 Billion by 2030

The global market for Multiple Sclerosis Drugs estimated at US$21.3 Billion in the year 2023, is expected to reach US$33.8 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Immmunomoderator Drugs, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$13.2 Billion by the end of the analysis period. Growth in the Immunosuppresant Drugs segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 6.6% CAGR

The Multiple Sclerosis Drugs market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.4 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Key Trends and Drivers

Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder characterized by the immune system attacking the myelin sheath that covers nerve fibers, leading to disrupted communication between the brain and the body. The treatment of MS has improved dramatically with the introduction of disease-modifying therapies (DMTs) that help reduce the frequency and severity of attacks, slow disease progression, and manage symptoms. These therapies include injectable medications, such as interferons and glatiramer acetate, oral drugs like fingolimod and dimethyl fumarate, and infusion treatments such as natalizumab and ocrelizumab. The diversity of available treatments allows personalized care plans that are tailored to the severity of the disease, the specific symptoms experienced by the patient, and their lifestyle preferences.

In recent years, the focus of MS treatment has shifted towards earlier intervention and more aggressive treatment strategies to prevent irreversible neurological damage. Newer therapies that target specific pathways involved in the MS disease process are in development, offering potential improvements in efficacy and safety compared to older therapies. Research is also exploring the role of lifestyle factors, rehabilitation, and symptom management therapies to improve the quality of life for MS patients. This holistic approach to MS care is increasingly recognized as essential for managing the disease effectively.

The growth in the multiple sclerosis drugs market is driven by several factors, including ongoing advancements in the understanding of MS pathology that lead to novel therapeutic targets and drug development. Increased prevalence of MS across the globe and the rising demand for more effective and safer treatments fuel the market's expansion. Furthermore, the approval of new and innovative drugs by regulatory bodies accelerates their adoption in clinical practice. The market is also supported by robust patient advocacy networks that promote awareness, education, and access to new treatments, ensuring that patients benefit from the latest advances in MS care. Additionally, improvements in diagnostic technologies aid in earlier detection and treatment initiation, which is critical for optimal management of the disease.

Select Competitors (Total 49 Featured) -

• AB Science SA
• Acorda Therapeutics, Inc.
• Banner Life Sciences
• Biogen, Inc.
• Biohaven, Ltd.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Janssen Sciences Ireland UC
• MediciNova, Inc.
• Novartis International AG
• Opexa Therapeutics, Inc.
• Sandoz Group AG
• Sanofi SA
• Teva Pharmaceuticals USA, Inc.
• TG Therapeutics, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Multiple Sclerosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Innovations in Neuroprotective Treatment Approaches
  • Rising Prevalence of Multiple Sclerosis Worldwide
  • New Developments in Disease-Modifying Therapies (DMTs)
  • Clinical Trial Landscapes and Their Role in Therapy Advancements
  • Regulatory Incentives for Accelerated Drug Approval
  • Technological Advancements in Drug Administration
  • Increased Awareness and Diagnosis Rates Boosting Treatment Adoption
  • Global Expansion and Localization of Drug Production
  • Market Challenges Related to High Treatment Costs
  • Advocacy and Educational Efforts Improving Treatment Outcomes
  • The Future of Treatment: Potential for a Cure and Preventive Measures
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Multiple Sclerosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Multiple Sclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Multiple Sclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immmunomoderator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immmunomoderator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Immmunomoderator Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunosuppresant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunosuppresant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Immunosuppresant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Interferon Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Interferon Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Interferon Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• JAPAN
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• CHINA
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• EUROPE
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Multiple Sclerosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• FRANCE
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• GERMANY
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of World Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of World Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of World Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030

IV. COMPETITION